Erectile Dysfunction Drugs Market to Exceed Approximately $4079.9 Million by 2028, According to Brandessence Market Research
LONDON, September 23, 2022 /PRNewswire/ — According to the report published by Brandessence Market Research, the Erectile Dysfunction Drugs Market generated $2,319.8 million in 2021, and should reach $4079.9 million by 2028, growing at a CAGR of 8.4% from 2021 to 2028.
Global Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Drug (Cialis, Stendra/Spedra, Staxyn/Levitra, Viagra), By Distribution Channel (Hospital Pharmacies, Online Pharmacies , retail pharmacies), based on region and segment forecast for 2022-2028, Growing number of erectile dysfunctions, increase in geriatric population and increasing number of chronic diseases are some of the major factors driving the growth of the global erectile dysfunction drugs market.
Get a sample report on: https://brandessenceresearch.com/requestSample/PostId/2086
Erectile Dysfunction Drugs: Scope of the Market
The global demand for erectile dysfunction drugs market is going to witness high growth in the coming years. the growth rate is going to be high due to increasing burden of lifestyle related diseases and increasing adoption of sedentary lifestyle where incidences of erectile dysfunction are increasing all over the world . According to the World Health Organization, a large portion of the male population is affected by the disease every year. Therefore, there is an increase in disease prevention drugs that is going to be imminent.
Erectile Dysfunction Drugs: Competitive Analysis
The pandemic has also had a significant impact on the market. For those who want to know how many drugs are on the market for erectile dysfunction, there are companies that manufacture drugs such as sildenafil (Revatio, Viagra), vardenafil (Levitra, Staxyn), tadalafil (Adcirca, Cialis) and avanafil (Stendra) in addition to a few others.
Some of the prominent companies in the market are Pfizer Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Sanofi, Sun Pharmaceutical Industries Ltd, Bayer AG, Petros Pharmaceuticals, Inc., VIVUS, Inc., Auxilium Pharmaceuticals, Inc., and Adamé. The companies are working on innovating their products and maintaining their health standards so that no recalls occur in the future.
Based on the dose, generic sildenafil is one of the most popular drugs because it is often offered at a lower cost than Viagra. Therefore, drug availability could lead to higher prescription rates and market expansion. As the prevalence of this disease increases with age due to comorbid conditions such as obesity, diabetes, among others. People with hormonal, drug, neurological and other diseases are at higher risk of contracting this disease and drive the growth of erectile dysfunction drugs market.
People with diabetes who are in low- and middle-income countries will often face this difficulty. Market growth is going to be hampered by lack of healthcare infrastructure and manufacturing errors. There are generic drug recalls that occur due to a production defect. This type of recall will have a gap in the supply of drugs used to treat erectile dysfunction.
Petros Pharmaceuticals has launched two self-screening studies for erectile dysfunction drug STENDRA (avanafil)
On January 18, 2022; Petros Pharmaceuticals, Inc., a leading provider of men’s health therapeutics, has launched two self-screening studies for its erectile dysfunction (ED) drug STENDRA (avanafil). The results of these studies lead to potential over-the-counter (OTC) status for STENDRA (avanafil) in the United States. It is part of a more comprehensive data set the company plans to submit to the Food and Drug Administration (FDA).
Get the methodology at https://brandessenceresearch.com/requestMethodology/PostId/2086
Increase in the number of erectile dysfunctions, increase in the geriatric population and growth Number of chronic diseases are some of the major factors driving the growth of the market
One of the major growth drivers for the erectile dysfunction drugs market is the growing number of erectile dysfunctions (EDs). Due to the increase in the adoption of a poor lifestyle, diabetes, obesity, and cardiovascular disease are on the rise leading to problems such as erectile dysfunction as people age. The current lifestyle of young people in many emerging countries is very stressful, which translates into increased consumption of alcohol, tobacco, fast food or prepared meals. Due to these factors, overall health and fitness are compromised, increasing the chances of erectile dysfunction. Moreover, as the elderly population grows, so does the number of ER patients, which is a significant driver of the global erectile dysfunction drugs market throughout the forecast period. For instance; according to Johns Hopkins Medicine, by 2025, the prevalence of erectile dysfunction is estimated to be around 322 million worldwide.
Drugs for erectile dysfunction: segmentation analysis
The other segment is expected to witness the lucrative growth of the market in the coming years owing to the larger application base and availability of ED drugs such as Mvix (mirodenafil) and Helleva ( lodenafil carbonate) among others. These are used to treat adult patients with erectile dysfunction. The rise in approval of over-the-counter ED products provides easy access for patients with the condition. Innovation is going to be at the forefront of market growth.
By distribution channel
Drugs for erectile dysfunction: regional analysis
The North American region dominates the market owing to the presence of most companies in the market and the growth of a sedentary lifestyle. However, it will be the Asia Pacific The market is going to be the highest growing market as the region is going to see the cases of diabetes which cause this disease and increasing the size of erectile dysfunction drugs market.
The Special Requirement Erectile Dysfunction Drugs Market report is also available for the region below:
Germany, France, United Kingdom, Italy, Spain, Sweden, Netherlands, Turkey, Switzerland, Belgium, Rest of Europe
South Korea, Japan, China, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC
Mexico, Colombia, Brazil, Argentina, Peru, Rest of Latin America
Middle East and Africa
Saudi ArabiaUnited Arab Emirates, Egypt, South Africa, Rest of MEA
Get full access to all reports: https://brandessenceresearch.com/pharmaceutical/erectile-dysfunction-drugs-market
At 12.82% CAGR, the omega-3 market will hit $4215.7 millionWorldwide by 2028
At 6.7% CAGR, the clinical microbiology market is expected to reach $7,691.4 million by 2028
With a CAGR of 6.3%, the acne treatment market is expected to reach 19.03 billion globally by 2028
At a CAGR of 4.5%, the microalgae market is expected to reach 4,996.8 million by 2027
At 10.1% CAGR, Monoclonal Antibody Market Size is Expected to Exceed $282.8 billion by 2027
The nutricosmetics market is expected to reach $11,385.6 million by 2027 at a CAGR of 7.82%
The Active Pharmaceutical Ingredients Market is Expected to Reach $284.4 billion by 2027 at a CAGR of 6.4%
The bio-pharma market is expected to reach $703.28 billion by 2027 at a CAGR of 12.5%
Anticoagulants Market by Drug Class (NACO, Eliquis, Bevyxxa, Xarelto, Savaysa & Lixiana, Pradaxa, Heparin & LMWH, Vitamin K Antagonist, Others), by Route of Administration (Oral Anticoagulant, Injectable Anticoagulant), by Application (atrial fibrillation and heart). Stroke, Stroke, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Others, Industry Analysis, Trends and Forecast, 2021-2027
Quercetin Market Expected To Reach $406.58 million in 2027, growing at a CAGR of 6.53%
The Digital PCR Market Size is Expected to Reach US$955.1 million and grow at a CAGR of 9.35% over the forecast period from 2022 to 2028
The Diabetes Care Devices Market is Expected to Generate Revenue of $45.09 billion by 2028, globally, at a CAGR of 8.1%
Detailed Analysis of Anthrax Vaccines Market 2022, Trade Statistics, Trends and Top Companies by Forecast to 2028
Medical Tricorder market size is $5,411.2M in 2028 with a CAGR of 6.75%
The gene panel market is expected to grow at a CAGR of 20.1%, valued at $2263.4 million Growth, Industry Trends, Value, Analysis and Forecast to 2028
i-Factor: live market intelligence platform
I-Factor is our seal guaranteed to keep our customers ahead of the competition, always. This knowledge platform provides real-time updates on key economic indicators, competitive landscape, changing demand, trends, custom regional insights, and more. The platform visualizes key data points to help make decision-making agile, reliable, and holistic. Sign up for a free trial here at https://brandessenceresearch.com/i-factor/login/userRegister
Brandessence Market Research & Consulting Pvt Ltd.
Brandessence Market Research publishes market research reports and business information produced by highly qualified and experienced industry analysts. Our research reports are available across a wide range of verticals, including aviation, food and beverage, healthcare, ICT, construction, chemicals and more. The Brand Essence Market Research report will be most suitable for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs and managers, governments, agencies, organizations and PhD students. Students. We have a delivery center in Pune, India and our sales office is in London.
Follow us: LinkedIn
View original content: https://www.prnewswire.com/news-releases/erectile-dysfunction-drugs-market-to-surpass-around-usd-4079-9-million-by-2028–says-brandessence- market-research-301631843.html
SOURCE Brandessence Market Research and Consulting Private Limited